1 week Ago By Defense World Staff
Corebridge Financial Inc. raised its position in shares of Wave Life Sciences Ltd. (NASDAQ:WVE – Free Report) by 10.
7% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 45,824 shares of the company’s stock after buying an additional 4,423 shares during the quarter. Corebridge Financial Inc.
’s holdings in Wave Life Sciences were worth $567,000 at the end of the most recent quarter. Several other institutional investors and hedge funds have also recently bought and sold shares of the company. Vanguard Group Inc.
increased its holdings in shares of Wave Life Sciences by 10.2% in the 4th quarter. Vanguard Group Inc.
now owns 3,182,512 shares of the company’s stock valued at $39,368,000 after acquiring an additional 294,956 shares during the last quarter. Emerald Advisers LLC boosted its holdings in Wave Life Sciences by 9.7% in the fourth quarter.
Emerald Advisers LLC now owns 3,162,369 shares of the company’s stock worth $39,119,000 after purchasing an additional 280,859 shares during the period. State Street Corp boosted its holdings in Wave Life Sciences by 2.6% in the third quarter.
State Street Corp now owns 2,321,248 shares of the company’s stock worth $19,034,000 after purchasing an additional 57,822 shares during the period. Geode Capital Management LLC increased its stake in Wave Life Sciences by 14.3% during the third quarter.
Geode Capital Management LLC now owns 2,269,664 shares of the company’s stock valued at $18,615,000 after purchasing an additional 283,419 shares during the last quarter. Finally, FMR LLC raised its holdings in shares of Wave Life Sciences by 174.5% during the third quarter.
FMR LLC now owns 1,540,190 shares of the company’s stock worth $12,630,000 after purchasing an additional 979,110 shares during the period. Institutional investors and hedge funds own 89.73% of the company’s stock.
Wave Life Sciences Stock PerformanceShares of WVE stock opened at $5.80 on Tuesday. Wave Life Sciences Ltd.
has a 1 year low of $4.25 and a 1 year high of $16.74.
The firm has a market capitalization of $890.22 million, a PE ratio of -5.23 and a beta of -0.
93. The stock has a fifty day moving average of $10.17 and a two-hundred day moving average of $11.
77. Wave Life Sciences (NASDAQ:WVE – Get Free Report) last issued its quarterly earnings data on Tuesday, March 4th. The company reported $0.
17 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.34.
The business had revenue of $83.75 million for the quarter, compared to analysts’ expectations of $25.60 million.
Wave Life Sciences had a negative net margin of 66.50% and a negative return on equity of 280.57%.
Equities research analysts predict that Wave Life Sciences Ltd. will post -1.14 earnings per share for the current fiscal year.
Insider Transactions at Wave Life SciencesIn related news, CEO Paul Bolno sold 169,025 shares of the firm’s stock in a transaction dated Friday, March 7th. The stock was sold at an average price of $9.57, for a total transaction of $1,617,569.
25. Following the completion of the transaction, the chief executive officer now owns 338,351 shares of the company’s stock, valued at $3,238,019.07.
This trade represents a 33.31 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website.
Also, Director Christian O. Henry sold 10,500 shares of the business’s stock in a transaction dated Thursday, March 20th. The stock was sold at an average price of $9.
77, for a total transaction of $102,585.00. Following the completion of the sale, the director now owns 16,115 shares in the company, valued at approximately $157,443.
55. This trade represents a 39.45 % decrease in their ownership of the stock.
The disclosure for this sale can be found here. Company insiders own 29.10% of the company’s stock.
Wall Street Analyst Weigh InSeveral research analysts have recently commented on the stock. Jefferies Financial Group started coverage on shares of Wave Life Sciences in a report on Tuesday, February 25th. They issued a “buy” rating and a $26.
00 price target for the company. HC Wainwright restated a “buy” rating and issued a $22.00 target price on shares of Wave Life Sciences in a research note on Wednesday, March 26th.
Finally, StockNews.com upgraded Wave Life Sciences from a “sell” rating to a “hold” rating in a research report on Saturday, March 8th. Two analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company’s stock.
Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $22.60.Get Our Latest Stock Report on Wave Life SciencesWave Life Sciences Company Profile (Free Report)Wave Life Sciences Ltd.
, a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.Read MoreFive stocks we like better than Wave Life SciencesDo ETFs Pay Dividends? What You Need to KnowOptions Activity Points to More Volatility for Palantir StockWhat is a Low P/E Ratio and What Does it Tell Investors?NVIDIA Stock: Oversold, Undervalued — How Low Can It Go?Why Special Dividends Can be a Delightful Surprise for Income InvestorsMicroStrategy Sees Insider Buy-Sell Action in Q1Want to see what other hedge funds are holding WVE? Visit HoldingsChannel.
com to get the latest 13F filings and insider trades for Wave Life Sciences Ltd. (NASDAQ:WVE – Free Report)..
